Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19

Overview of attention for article published in JAMA: Journal of the American Medical Association, December 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 16 news outlets
blogs: 3 blogs
twitter: 153 X users

facebook: 1 Facebook page
reddit: 1 Redditor
podcasts: 1 podcast

Readers on

mendeley: 30 Mendeley

So far, Altmetric has seen 3 posts from 3 blogs.

Fluvoxamine Does Not Shorten Duration of COVID-19 Symptoms

Physician's Weekly, 29 Nov 2023

TUESDAY, Nov. 28, 2023 (HealthDay News) — Fluvoxamine does not reduce duration of COVID-19 symptoms in patients with mild or…

TWiV 1064: Clinical update with Dr. Daniel Griffin

This Week in Virology with Vincent Racaniello, 25 Nov 2023

In his weekly clinical update, Dr. Griffin discusses progress toward measles elimination, risk of severe coronavirus disease…

Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms

news-medical.net, 22 Nov 2023

Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19.

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.